GW Henssler & Associates Ltd. grew its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 2,297 shares of the company’s stock after acquiring an additional 122 shares during the period. GW Henssler & Associates Ltd.’s holdings in Johnson & Johnson were worth $406,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in JNJ. Veracity Capital LLC raised its position in Johnson & Johnson by 1.2% in the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after purchasing an additional 59 shares during the last quarter. Sandy Cove Advisors LLC raised its position in Johnson & Johnson by 1.6% in the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after purchasing an additional 60 shares during the last quarter. LCM Capital Management Inc raised its position in Johnson & Johnson by 0.7% in the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares during the last quarter. Arbor Investment Advisors LLC raised its position in Johnson & Johnson by 2.3% in the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares during the last quarter. Finally, Mason & Associates Inc raised its position in Johnson & Johnson by 4.9% in the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.
Insider Transactions at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.20% of the company’s stock.
Analysts Set New Price Targets
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $163.60 on Tuesday. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The firm has a 50-day moving average price of $157.86 and a two-hundred day moving average price of $167.04. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35. The company has a market capitalization of $426.06 billion, a P/E ratio of 34.23, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period last year, the firm posted $2.67 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.91%. Johnson & Johnson’s payout ratio is 94.56%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Insiders Drive Volatility For Keurig Dr Pepper
- After a 40% Drop, Analysts Remain Bullish on Impinj
- Visa Charges Higher After Better-Than-Expected Q2 Report
- onsemi Puts A Bottom in Chip Stocks, Heads For New Highs
- Can Teladoc Stock Be Resuscitated?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
